0001193125-24-025941.txt : 20240207 0001193125-24-025941.hdr.sgml : 20240207 20240207075902 ACCESSION NUMBER: 0001193125-24-025941 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240207 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240207 DATE AS OF CHANGE: 20240207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263407249 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 24602222 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 8-K 1 d678628d8k.htm 8-K 8-K
false 0001750149 0001750149 2024-02-07 2024-02-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 7, 2024

 

 

INHIBIKASE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-39676   26-3407249
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

3350 Riverwood Parkway SE, Suite 1900  
Atlanta, Georgia   30339
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (678) 392-3419

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.001 par value   IKT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events.

On February 7, 2024, Inhibikase Therapeutics, Inc. (the “Company”) issued a press release announcing preliminary outcomes of its pre-new drug application meeting held on January 19, 2024 with the U.S. Food and Drug Administration on the pathway for approval for IkT-001Pro, the Company’s prodrug of the anticancer agent imatinib mesylate, in blood and gastrointestinal cancers. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause the Company’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to enroll and complete the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease, our ability to successfully apply for and obtain FDA approval for IkT-001Pro in blood cancers and whether the FDA’s signed meeting minutes differ from written pre-meeting comments or oral discussion that occurred during our pre-NDA meeting for IkT-001Pro. Additional factors include our ability to successfully conduct pre-clinical and clinical studies, and whether results of our animal studies translate to a clinical benefit in humans, as well as our need for additional financing and other such factors that are discussed in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this report speaks only as of the date of this report. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Number    Description
99.1    Press Release dated February 7, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 7, 2024     INHIBIKASE THERAPEUTICS, INC.
    By:  

/S/ MILTON H. WERNER

      Milton H. Werner, Ph.D.
      President and Chief Executive Officer

 

-3-

EX-99.1 2 d678628dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA

Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood

and Gastrointestinal Cancers

- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated

Parkinson’s disease -

-

BOSTON and ATLANTA, February 7, 2024 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced preliminary outcomes of the Company’s discussion with the U.S. Food and Drug Administration (FDA) on the path to approval of IkT-001Pro in blood cancers, the Company’s prodrug of the anticancer agent imatinib mesylate.

“We were pleased with the discussion we had with the FDA as we begin the process of building our first NDA package needed for approval,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase. “Our bioequivalence studies were presented to the FDA and we were given specific guidance on the manufacturing requirements necessary to complete the NDA. The FDA acknowledged that the appropriate approval path appears to be 505(b)(2) and we plan to seek all 11 indications for which imatinib mesylate has been approved, including its use in children. There is significant work ahead of us as we discuss these details with potential commercialization partners and carry out the work needed for the NDA submission,” noted Dr. Werner.

On January 19, 2024, members of the Company along with its medical oncology consultants met with the FDA Review Team from the Division of Hematologic Malignancies to discuss the Company’s bioequivalence studies of IkT-001Pro. During the meeting Inhibikase inquired whether additional clinical studies may be needed to seek approval and discussed manufacturing and quality control requirements for approval. The Review Team acknowledged that the 505(b)(2) pathway appears to be the appropriate pathway for approval of IkT-001Pro and indicated that, pending formal review of the Company’s clinical data, clinical studies completed to date indicate that 600 mg and 800 mg IkT-001Pro provides similar exposures to 400 mg and 600 mg imatinib mesylate, respectively. These preliminary outcomes from the meeting are subject to formal review of the NDA package. In addition, given that imatinib mesylate is approved for use between 300 mg and 800 mg once daily for a variety of blood and gastrointestinal cancers, the Review Team advised that if the Company intends to seek approval across all currently approved indications, Inhibikase should evaluate additional doses as needed to measure the safety, tolerability and bioequivalent dose of IkT-001Pro that would deliver up to 800 mg, the highest approved dose of imatinib mesylate. The Review Team also discussed the possible difference between IkT-001Pro and imatinib mesylate absorption in the gut and recommended the Company evaluate whether IkT-001Pro and imatinib mesylate behave differently with respect to certain gut transporters that regulate absorption. Inhibikase is in alignment with the FDA and is initiating the necessary pre-clinical tests to evaluate this further to ensure that delivery of imatinib by IkT-001Pro mimics imatinib mesylate in all respects. Finally, a number of recommendations were discussed to prevent the mix-up between 001Pro and imatinib mesylate either at the pharmacy or by patients for two drugs delivering the same active ingredient. A comprehensive use-related risk analysis will be conducted as part of the manufacturing and quality control development program to identify ways to discriminate the two drugs by appearance, pill size and dosage. The Company will request milestone-based meetings as it completes the manufacturing and quality control processes to ensure are it is meeting the manufacturing requirements for approval.

The Company has continued to make progress in its evaluation of risvodetinib in the 201 Trial in Untreated Parkinson’s disease. As of February 7, 2024, 32 sites are open and actively evaluating prospective trial participants. 51 participants have been enrolled, 19 prospective participants are in medical screening and 46 potential participants are being evaluated for suitability to initiate medical screening. Twenty-three participants have completed the 12 week dosing period. Nine mild and one moderate treatment-related adverse events have been reported across all enrolled participants taking risvodetinib.

About IkT-001Pro

IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, imatinib (marketed as Gleevec®). Imatinib is commonly taken for hematological and gastrointestinal cancers that arise from Abl kinase mutations found in the bone marrow or for gastrointestinal cancers that arise from c-Kit and/or PDGFRa/b mutations in the stomach; c-Kit, PDGFRa/b and Abl are all members of the Abelson Tyrosine Kinase protein family. IkT-001Pro has the potential to be a safer alternative for patients and may improve the number of patients that reach and sustain major and/or complete cytogenetic responses in Stable-Phase Chronic Myelogenous Leukemia (“Stable-Phase CML”) and/or reduce the relapse rate for these patients. In preclinical studies, IkT-001Pro was shown to be as much as 3.4 times safer than imatinib in primates, reducing burdensome gastrointestinal side effects that occur following oral administration. Imatinib delivered as IkT-001Pro was granted Orphan Drug Designation for Stable-Phase CML in September, 2018.

About Inhibikase (www.inhibikase.com)

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company’s RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with an office in Lexington, Massachusetts.

Social Media Disclaimer

Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use X, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and

uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to enroll and complete the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease, our ability to successfully apply for and obtain FDA approval for IkT-001Pro in blood cancers and whether the FDA’s signed meeting minutes differ from written pre-meeting comments or oral discussion that occurred during our pre-NDA meeting for IkT-001Pro. Additional factors include our ability to successfully conduct pre-clinical and clinical studies, and whether results of our animal studies translate to a clinical benefit in humans, as well as our need for additional financing and other such factors that are discussed in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:

Company Contact:

Milton H. Werner, PhD

President & CEO

678-392-3419

info@inhibikase.com

Investor Relations:

Alex Lobo

Stern Investor Relations, Inc.

alex.lobo@sternir.com

# # #

EX-101.SCH 3 ikt-20240207.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 ikt-20240207_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 ikt-20240207_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g678628g0207083653209.jpg GRAPHIC begin 644 g678628g0207083653209.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 07, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001750149
Document Type 8-K
Document Period End Date Feb. 07, 2024
Entity Registrant Name INHIBIKASE THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39676
Entity Tax Identification Number 26-3407249
Entity Address, Address Line One 3350 Riverwood Parkway SE
Entity Address, Address Line Two Suite 1900
Entity Address, City or Town Atlanta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30339
City Area Code (678)
Local Phone Number 392-3419
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol IKT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d678628d8k.htm ikt-20240207.xsd ikt-20240207_lab.xml ikt-20240207_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d678628d8k.htm": { "nsprefix": "ikt", "nsuri": "http://www.inhibikase.com/20240207", "dts": { "inline": { "local": [ "d678628d8k.htm" ] }, "schema": { "local": [ "ikt-20240207.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "ikt-20240207_lab.xml" ] }, "presentationLink": { "local": [ "ikt-20240207_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-07_to_2024-02-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d678628d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-07_to_2024-02-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d678628d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.inhibikase.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001193125-24-025941-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-025941-xbrl.zip M4$L#!!0 ( & _1UB:T$%G81( )!J . 9#8W.#8R.&0X:RYH=&WM M/6MSXKBRW_,K5.R=LTE5>!C( Y+A%$O(#&6)" M/OY>[S1:K=__63NX'(30#)IZLNHP_C$S",.@FL^/>\+-26;G'ORG/'S(%PO% M4L8TC&0VG 1,)JW[5/9ROGC(QU]FFGN^YT7#I/%H-,JIX;&#$XH\]LA#HRRT M8H+;<;^QR[W'F6ZCDNID52J5O/H:-UUHF4Q0+!1*>?SP/> MXX_0(F?[0P2^7"@6SA) )%\&!@QMY?_Z>M.Q!VQ(L]R3(?7L9)(H%"M!JN3A M:P*-],M%ZVP-_*9%TF&\JJT%;3U8+?OKC_;-M'FXO/VT:3X4U)-]7PQI"/R" M(YUD"\5L\30U2!;X86:@F#\VC7.>+5D)+F%ROFZI!RR$)*L'N6_3OB3Q\S#=\+F1=FN\"; M&6+KIX^9D(W#O!HN#[WR>D!"R&7/=R:U2X<_$1E.7/8QXW 9N'2"S,\R-7+) MQU5LS83YG3L.\_3OT.16,GH-])IM:GKF27^9F9%F;&'I\54'_#]'\W/4#- MI 'S"^JV/(>-O[!))@7?B@;/@[-6 !$Z.RE8Y8Z\6>S, M M6S]".A'Y785 UV%;&VP&[GY D"/WUC!F$C? MY0[YK:#^9&K_^,TZ+5QR0^NT5:?[5^%R__=0DC;NO7UN=3NON]E4P%G4TNEB8B6QCBW'5]5W[ZVH'X\[6^R% M+78BR*!JVLW;+FDW[^_:W>^O6.XC(2/JA23T28?9R'G$*A%?$.ODT#GZ_@#Z M?1(.&,(6"1YRZ-\C++HW"$Z;!;X(R6'\S"BX M-TR&A#U!2R+49^8<53=KAWOE(S6UZ_1L-:$#.5058=6! 8;0?>#0R00@8EY: MC8"W>0J<4R[O@O-6,I..\-GO@$F/[\!:^O,+JCL O<'#;'%-0$+EP+ M9XP*0B7I!,S&:,@AW",\E*0Q@(B&B7FU]\[M*[C]-8@YN QISV7$9JXK VIC M:C-3R*CG@#I._&RF,DNU?=>E@635^)?U+#+/3QH;5J'PP>"N6C!@5@MQM > M"?6O,QM"ELH?,-I/?WAB(N0V=0U:]4KG&YG>Q>UZQR NM$X/94%Q/0G)BQ"%@C_":>=-8$5,.#, MI2,PC8NF#Y>$.'>VH7["X_/-OP,ZK[G+X%L/-,V+M?YY 3-)5K94.3T[_85P MTZ7CEDF'V0H9KT:4E:D53[.EZA$$J.#.W#*!?D7 M^.32X2ILN.R)/'KK,R)\]",SR&'#'PZYE#'P*"U$<\&/#7>KW2'-8>#Z$R84 MY+.,3&[]W-$"O\$_:&__8\WW26$G!KA\_DL;X+KC"":E^7$#+JGU"HU8S-1* MI9,":7. =.3[#KFGXG%$)Z33G%>0QYO"F$70BJ\ K92I=2(.RLRJ% K[,FM+ MZ/.C\DZ\E)VP3P-^O1-=?^2]@D+E3*T>NA"JT9>RBK)6=^(>/#ZN=J7WYC^> MGV1JGY@/Z%T ]GM9DIT2]-Z'M;O_PX,7^>%3-)V"0BB42K^H=V20A8F&>P$< MQP/JDN:8V5$("I#<]<%",_EC^Q9 8X)$WLJ!>&:>=2<9G6D*YQ^_G1>MLPM) MNLQEP<#W8N_M&)U0-T(?A-2!;=2"UN1;45UANU_4+ZW$6QYY)P+/MR@)JA3R0?1FY(/>9'TIT0"7(E M^Q/5TW3P>X ''3Z9+2JZ8T^ >55K[O]BB0/ 3&2VO="L)?.2N7 M+Q:5[A;!0)H3R"SQR:OU\ERQ4Z9F< /(2".'!*DMX'8$#%4NGAB.G]MYQ0W7 M0^N,-*[;I%@JY*#AD=8"6R49WCE\%QS> 65N SV\AZ^@"4$=NGMC[TKA9V+O M*6)@:(V91=ZVRC1K%5/L/5--D#!WN9#3+=_Y^ZWY^UXPU-Y82JLJI-"&"PB= M7N =;\WGUL_$YX"@K)W"T$9];I6=;/&P=[0=U^NV[WS_G?F^)67$Q)MP?_'7 MYOX2RY8/[>VXW[3=S/T[CW-2;I8./)B T"585IZG9-D$(K""U2'%C[^K<_Y> MD[';M.46\?^*)0YXR+)(TC7=/%TERZ@M ?$=JF4B53N M-6OZ4A1^;WP)BN*I]H,[DR$T.Y1'[QA;EY0T18&*P9BQ";J,P2,@#_!VJHIG M+<(/MWVW(6;4QF5B%7M*K%Z>9ZZ4,C5T4P!#G="W'X_)?Q6 WA8)J"!/U(V6 ME$]]EVV.5:@P8J(EY!5X*&=JK2_='WRQ,=UCA^=%];_S?B1*RL(&:.4$-!#X M([=4.O3?FC?(5RH>64AN;AI+\?1FOE7+<] _9*0W(;;*)\.(CR#B3%4QS25[ MN234(^!#^ ]-Y MO@H&(LE4*T"8V>3 L_MID3@>P =?!'OB$OH!*U// MQEP9M6VLM<7&>(K?H<*1>GO#616)E YI$HFD>32WD07&W01>? M[FY3[U<[(JQW]LS^WL'!:Y@+5:NI ?[7CFB=;Z^7J6N M5F[B 3R9(\])[IRNL -J"E#@,&*U_.&9=N'.(_%Y.RUPYM =UJW$=]D0\*8@ M"&<1H%*J@I8<.40]B^0H%BZ,V51/UL41>"TR C5-06-C"9( >X&C4,\#I6[K MG6KF\B&H>S$A?A2":6"J5 D//LVPP;)4 '3.@N4P#$ <$3W@AKP;EQR#.Z@L MQX"Y#H'G?U%ONCRKHM>GC1 NXENNDR/76! *AH9I@T8*D8F!Q MWC29T.<,0XA#@81 =P9&EJ+;A]P0DDHE9ZG)5%5#7%YOFB(T$Y)^&(&SD+WQ_4?D 55VB;E9N0:6O0A6%]W?1B0$4LX2EW M_@9^F%J3-MK'X=2OKYSDR)_,U*X0&=D#LGIR],5Z#-CL226+>[J@1=(^ Y=1 M@+5)5Z>@T*P9"KTO&H)1@Q-Z-,#S<:>F#R.R6'>LW$ D"R\'M+)_*L1=]WY=W+@ M1ZXS_U9I" YZ:7&ZP 6?-GD)^):@;UTJP$M7XJ[HX.N TV/( 4_,H ;=>5B? M5.A;UHT*-E/19*[RF:RA:0YMB&3KJ(ZCXC5&3JQOY]64;81)8]+LL2",%.S- M,%#/.=)!_T(7A!7T(?(6$5P^ZMZ19]XA+QR;9)N-Z ;]&<J9 !A]L ;]1L^ .09ST^,N1$8X*O.$[[H*42J 8Z%&"+AAI*OJ&ABF MVJBRN(#4)]]AVDC!E'A63JF;9R7LQ ,2QZ"S%4XNACO1Z@QHZ4K&FZ^[9B?8= **JT>;3%FG&BVZMZ M/$D,_#/QE8O[UR$J0 E#E!N>7,$Q,P0$5>Y$('E;@6M#&(G.>CRG8CKS#OI& MCA+0-*5B]@?%I:#PP$5*FNH\!/I)"!:=#M5C'NN#+P-,,(B&J"=1?X\8\KE4 M WF,Z:0%32U;9R< AXH7U?S:**9E%-6-H9^V7SBK7X%L002/-HP7!8XY[ZG312J!M!*R MXX1%T(P;/D$@,.7$O>1BR6/2C\((:08VV_6#J2!BYQ%'!<7&-@O4)0U@K-') M$7BWH_%R5!Y6!Q\J1I^BU*4CN> !SUWM])I2E?<\P$7E)\X#7"?)SE2,HL50 M15H[2@X\*V8Y=(Z2Z==P;G'/I1R[X>PM:CD.#G0UA_KAY,W/;>HO3E;47U3> MKOYB^]H)?:#GF?N!6YXC73/M%9.VX,HOGW*Q0?D2KEI88'S:!#[D5WX!#P-9 M"N2]^&;G61>5R=+U8ZID/TC7.ZV4Z)MCG=.S\]/BN+=;)L"6[/PZ$<9T MF(!P9AQ_G?PS<;*O+S#KL0%U^W&Z0_GXI@&FBB,/4Q8X')!BX M8F+/.6_YI M?8YY+V.N=ELY$MO['2NO MERF!55HSL"XB1Q?N;,_!MH^EA;X_V4U>7&;M=W M:"Q'Z4[&G)K.TL:+#E]JO%&F5EAO]6G6?.^VV7=Q!O9(KWV,6?MC4MW'M2_/ MK'3=4*CQ3,N4[^3)U]9-]^Z6?,Z1/YOMVV;[C>M9?VZNV NG?>5N"&8;*<*$ MA[=6W ]R5ZMTRSM1WH0H&,2IK365%FH,..LOW. BEH4':]S:!9^)+"09-OW7 M#'ORCK.EK';_#N;#DLN\_D]QU/^74_M_4$L#!!0 ( & _1UADS88J A( M %$\ 1 9#8W.#8R.&1E>#DY,2YH=&WM6UMSV\C1?6<5_\.4MK)E5Y'4 MQ3?=S HMR3:SND6BL]GO;0 ,R5F! (P!1#._/J=[9D" NEJQG#Q\V519 HF9 M[I[NTZ>[1_N?1R?'_?W/1X/#?KNU/QJ.CH_Z1__L[NST-O?7[:]XONZ^(/8_ MG!W^(3Y\.C@[/KMXO_;[Y^'H:$UW>&YVL"1GK28(%U+A8XVW._==F,I_HI%ND MV>Y&5NP)]WN0%D4ZLX_&:5)TC?Z7VMU<_CZ6,QTO=D=ZIHPX57-QD7'P?FWR]MWVVZWMR<;6QKN-[5=OW[S: MVMCI_9E-Z,71^[7CLT]GUG1-\6O[LOP_RH AGRA;<)B0!:^D46(T5;G,5%GH MT(A!DJ1E$N+U\US%>J83F2_$65F$*:V9CH4N#'3\>'8ZJKQBJ@O5-9D,U6Z2 MSK'86A]O=T\/!_OK],7^;6?T3$Y2T_%$J4(G$S'7Q5044R4^'@Y$FO"/Y[*8 MSN4"2^9BD&5Y>BUC^N41J@VO1MV-C*5,#6DUP9P\>P MM;$I1KF&P H'4$H^KUR;ZS2BL],!V;9,BES)0I%]A_=I\RP&'O;/97ZE$Y,F MO_ZR^?KMGA&1-HHBI_O?$*C[W&A!*G\XNQR=G0IRK<'H>' Z&G3:K8\JR$O M 2M->O,_%CK?=7"66Z\%3/1F!.H7.]2%VK M.,W(K>!XA8([X2Q))LU[%=BAJ ,@/'261GJ\8/\,TS(WJMT"[MWE!1WQ,!BN MO-H%M)(_>_S 2FD>4;B2P5.2QZ_.D$N2# (58P4Q6N2I011@ R MZ8 [@IY+X$YKP%TL([*F0E@:H[%N!9)?>I<]\9'0#,*T6X=Y.1&#".MI0 P" M%-]] 2!]Z9$TD_1B*J1'46SU- P-&$-#BUR=V^3%#A')X[21"1TV?5W !9)" MZ)FTJ &5%V3BGGAN\.M;__Q=B;G*88V83BU:FK-N8B6F,FJF(VGH<: @@K5F MGH8$CM P*'4/"!\58YZ80R*BP=WA%#I\H%6$C2F#>]!T7-49J/KF>C5)RKO4&(W.B)SD;<=3+4:BZ-O*H3_7RMQ-AYK,B@$6$9CST7A&20) M=*J^EAK;*5A>F**,M#).>RQ-,!610U0J8I>Y,\\$6R3"9"K4V$9,2AW1^7E? M@D'+L0R+,N<\0/OD:H85#=0ENY!/8VF*[E@5BE^"47J<;K!9NP7KP,EB%4U( MBJDLK*>0A3(DFD(M'94]%[\IF7/E<&I$-L6!R< MJ3S$C_I?-G@SF1>)QYI0YA8EV$J\4\VOG'6%*8.99A_V'I:D=,B5AUG7ZCU[ M9CI+Q-_@(O "N^_F#M(2Y9T.K#X+2*LFT.'(4L\ R>(S%7%Z2),PC=,)4Q-3 MQH5,^,.B&9P7ZEIC\Y&2,S'.TQE_<*BO-8+.V/*=V M/JLP=D<(I>/O8I\]#YV'-EPX@!SEK>5>G7 4P9NGBC.+C")-GD#>X7)H)<(, MF22HL*7R>Q\QY#).+WSS^K_=V! S:]AM^^,3M" 3 .T)4A!3,A?J6Y::,K=.^GJYA=OM!HQU MH"4!-F6'>,$'9]3M)*.*$>^&$F@&\/@3;]-NUFKM5M-LM:36@^-6_MEQV8)M M<1-=@9(>5_FT"4P#5P,! 3'RQ(9.8:.1!%C4-Q $VQ5-7O> MA&ZU:&K2W!CI,DF!$'<24 \=C9$PZ M6W_T3PWT&_XE Y#RC%.FXV:3TE*F7'%632(GCC_WZH \TEI9VJT?($V@IO)Z MJ3#Y#:4JTFYHE>OD28,JF3)25[A*( C*Z'P,IYX!,<)I7EBBFV&9[(5^0Y_4-KF /ZXS-R!F]@7(?>$U $>JDG!DROFS1QPNL'>UILVU ?+!> NCB97" MJ@'5TTE4AI3R@%G$1'T2>)A+N$J>G9-[2, &&)HK&2K7D?4KWI5S:G+UP=( M@6N"*Q*5U]+0F]D#_Q3YJH;L UGLMRC+^ZJ(H2 M\TB%7*EG$[%S=$J86$J;*H4^4!8U294K=MK?EU><"P M^\L._V]-_#X\''U^O[:YL?&7JHMU<'0Z.KKXGQLQ].NG3G6;;UG:E"JOU+)O M"8R@4L(W+&TEL-JS;#8W\>"+;V*V6W=UDA!Z7+_X/ENCL]81K[;@K.1>Y"1I M1G4EO$HZ8E9OH$)4S]B0"327NGFA0YU1G=,3;S8;#P2G%JY450+/C*E2W=QI M+-/X/GMI4A53B#>\Z]W\]=M:^5E_#?0GIVWHBQ[P+74SI2X\.Z&0MFE&W=P MT3G'RHMN,<636Y2H46HN*4VF=P \OY4OH%1Y6GG[AW1Q/_0' M 57V3\B/#TP-WOX0^9[0(X25JQX@%1/$:%P WD+@<+A5"\9E#QO/>L8TM$:1 M?1JR;;9'9#RPHJYGLUX\WZ)],0CBES?:S)VEB"]@NROELN"G6$&VVOXZ7^2_ XO[(VW/%)$P "O Z*4WQ- MEVT*5\3?5>@PTZ) !2+9<@ZZ>%5F95%UO4HNCMEF 4>0S/-T3OR#-KQW>5%; M_4$G"+N_Z:)&C=>Q^OGAIX\71$078 KN/7+=CE_8KPC-:>(!E0FJ M**)7VDIW=.&KV8)U]MY38HY:5F6OJ93O.%DV,WPO&'"=I9AE9H@MP, M7V(D=OU'HRH-N#D 7KK:2'G$ .:FM>>P-NKJ>0)TMF8&Y2K)-D:\ZKT6!<.5 MM3PLERR#5Y,0]!OMS-(3M@=E#B)J4E#J&\Y/W7:A4+B%_AC2,*2>/G)%.N<. M?TYQV1BRU(+:\78+%T_4%729^_)G>4;:T%2GW3I4U&>V$$KV7CTJ/F^5%1P# M1$,VMW]BWJH5IR_VO_3G\WE/+R<2\-3]]2_]ES\E5WW/*).3U'"[41]7GW#;F,8/ONRJ$QE4QLF=L/@B['(NK"7! D>A"@MU%=L2]\Q7\3(' M$'.ULJ"?$;.4=W+"+QZ& *CQ[\K@=#770!)UVP05IBON-19.-"MSD-3D$1W8 MQ\]Z74IQ:M ECB'U;<*B SS@**T/FJHC!US=:2KC$.R$E &0B\N%0?2* 0 I MFU(7@PI=8D]5,Z50X31A;J"LXZWR%E.M^AW04V56^?TSVV7SWQ5D[1;<2R-6 M7!_!M;2Q=J *)$6?(:BU#8K/[4!N7XW5O.K"W2-VFG1MA>"%)A_K.L!N- 2\ MO2\&)^??2]A^V7SSRC$V6]A88@1N1IB_J((+H=ENN:Z&)LRO)?,'5;$II9LF M7A6"&B)KW&1XU $B.V]L[%0M.DZ.%2>Q[>I86QYM RY,)U2P7=L0G:5TI6)< M)B'CQ^HU!O;VE<9CNT7#S:\H>0O.<@B'01'#461'?%(IH%O:\Y3$]&D\35\Y M5M]P9 7-"4ZD,> UI8$[F)^2H2Y3&JF*$YRC%(?:A+'$M_*?E(RNJ0U5ORUB M_(R YK*N)Z^J*R&"R JW <::!Y3!A#)\1G23HB*[6+8V_=N"?6?AA()JK M@-H0'1[V,RXI>P_E\NB@W1JCBN>6&$3+RB &CH9IXIOTB(G8N-%Z$((G-<.K M/CGAMC_-=)#Z_TF9OD,_?82W!FEZ53TXULF5BH8)/>"%\>R/M!R5@;*/*,_- ME$S8 ZDW&-MF0-T ,O 3<"=(AW.>4?FUIJN0RULY>*'PL_.QY\L+K-=N53-F MMPFU\U(88.+LAB#$ A>V#4^[?CS\*:[Z,QG )SHKET\Z_LZ#?4HY!FFA M^1#E5_,!Y:GF$QN@S6><"W7&I43C [IU4CVB!MER=DN69']R]S,2-;$UH34) MS$L:60^][344MD@O'&>N&>(;Z'>?@Q_ZWOT-KI=M5QR&OTE%W;136.NYB.#V MI3'EC*=1V.62[+^R:&U\[ =<-%HP]G;:_S>\GQJ7[1:E!C9HP46TO<44Z [,V[:0@/)*L/0>-U> DB-XWKLWQ'-7KC!=H^3#6?44:4K M3S3L2'V[J"Y24P FP_=*X&#C'L>U-[(49[M:#]IVPU8W">C#'W#+TN9B-ZYVTUXO*O4&EE,N 90L M:?K@[,U&G@-TB\<,W6GZZQ:J,5-[ M"$^Q^UFY++)@GQPX3*-(W2#SL=99G4NSEYWH\O%@.?/RH<@4)_%2/2L M=HV+Q_^VEDIKW0A0^42-:;Z8B&DYHQS3J)^Q$-TCL9Y7T]NR1C??L42(4V4C M3&5C!(X=:#D[(L4V-QD^4E)^T"Z;&]W?:O9HMQ[]VM^;=U.HJ1^KE?O- M-<) .AU]"U%O3YC_N9N./3%([LF)%EGTDM28#*F#]*/XK[B[WY][R.O?T MD"N=Y_V[(]J[NCAN!]._REFV)PZ.SFA[2\6>=_\'@__!+[Q]M]U]M;/5??5Z MTW3;*CX[@RV?X%%@47(D*^U!=+XV8+QS\5OP. 76JE4(I<0EG0G%5""[A:Z?X M#SA710(?I(2)AUF2:='<8)FL6.]LF=MB@15__0J \J5LKHBRJ<:13\0J#W=3 M(Q-MYJQTAKEEC8R<8O)"(XJH!_U_W ,,%<);[!HXXW8:0)W%YV?80XAKMW&* M4 LQ%=>4_E BGY=!-GC70Y0HUHB@R6*1S/4-(\,VN[>+QZ/(!H,AHXYPE&CL M0:10UWL0WCPE=?U#'D!NAP&0CD8C%JQ;DDJW&<&*_8BUQN#-G3-BVC@\TZ8Z MQ1EO)*$:]6_#I9@)+(,7=6J%RFWX;'HX;N;H+GF%MN8%/C'9U%./149B4_;] M\\77T&[1B0< A X45:V-@[81+W01[L>>A/I?<5>'V&_%:18/TX3((E"/ZMY1 M1& O%M*5]UE"UKUQL!"[JX?](O:+7:<_WOG/SL#VG?;QCWS\Z=N#XG\P$WZ" M$JTN7RJF-]B>7Q/%1='.K79Y>%WND2_JS6XN^#P<[3UX>Y"L3@UG,"_>;N\F1$$Y<6]N@[KA//@"V\&;Z?WDLLUM>^&<60I M[;)W.W]MM+7!IT9+$$O3/11M=]!?>EY/CMV?X!??)N?[WH?U \$ M*]N-6^UV)>NN,=N^QZN=_GUOM]IY0S__ U!+ P04 " !@/T=830!5C*H& M "D20 % &EK="TR,#(T,#(P-U]L86(N>&ULS9QO;]LV$,;?#^AWN'EO M-J"R8V7%$*-ID3G)$"QM@L;=A@U#(4N,34PF#5*.[6\_4G\:.:9D*CQ5>=%4 MD>Z>NT?^G<+(5MZ^WRQB>"!"4LY.>\/^40\("WE$V>RTMY)>($-*>R"3@$5! MS!DY[6V)[+U_]^J[M]]['IQ?7GT$#^9)LI2CP6"]7O>C>\HDCU>)DI3]D"\& MX'E%_'CR&?[(RHW@$XE)( DL ID0 ;^N:!R-_"/_>'@T]/M^.4V00.M!%"1D M!/[@EX&*^QF&_L@_&;UY [S.(9/.DVJ-B41#R3JYZHQ9?^-])>I;AY>?0>@ MSB*3Z;[3GCX7^:G83$7,S5[*^CA-&)Z^=+IB?G6!*XFNU!:F'D> QJ2FL#Z?5>WE\LEVJ>+))"(M(KOQ5FX=Y MU%R0^TQ5LY=*2A+V9_QA$!&J"3G6&Y[>T!W^H+[Y,N8*][.I3$00)KOU8GV* MN"AVIB9.>X:DP6Y#.NY,A#M:@0@+';5YP'\>,0BY>MV6B93E MN.'@EW@:&]O4)*DM/=V$>9_O#GG-A,K&!)%\)11>35[:U,^[5!G^*;3_?3MX MK/U26E67$$FNF_;KAN390F&N_B67<3"S1?))4D=(FEOGAH,N2!J$D)#\J@Q: MVAG(%AHM VG;K1N.%RRAR7:LRH@@OE(7X,WO9&N+945R1WC66^$U02ZXU@@B M89M5@+P$I#5 %7$&N,76RR W[]\-Z7,>KO3<3%3WMB3OYG0$L+%QOG_,!==] M'21*"V'0RLYHXK=9)M*R5QP,;XF@/+I@T;GZ=:8ICT^2.P;3;(77!&&@:A#$ M9C8K :H&Z")H^+;0NI%CZ_XQ%@N?R(SJ13)+/@8+:Z+-N9TN%2J,\.H8]X6" M20]WG?!8 70)I%5"&WT;%@G6S6. ?,5"+I9=06RG2*<*'K'&+8'>X:X5Q25>E8+<6+O>M6C$,P3/\8(S$610I S+_[YHR M,FPV#D:!3D>ASA(_$.@^ I6BN/CG^J^+#="5X(9AK6-:LV% _QE>VD'?=T7? M?W'H^[;H^VV@[W\[]"=KWAKZ2#:LT:_U@HC^6&W>B E?LV>!7TY_"=@;[)B@ M?PQ#0_ZI9$O ZS+ !>A"N+!C&ZA#W O!5 MQDS4/XE%0]^HVQ+_V8T-A4Y1#7<(6K%2-PD-_"".PRV721#_39?-[W&:%5[" M*)A-F09A)Q)M# RJ+0U!5@E4*]SY[-_ELVZ@:@_E!O?SCEK>+]\/Z\C("L- M<20JM-L:C*Q;,*Y MQ8*(F9J: MWP1?)W.U&%D&K.&#O!42G;[#5V^+'PQU?X^O1A:)]?R-L:(09)4@+X7T'E^+ M-@QO\C7V@C("&_63@TFJ[R9F3\0UY-^0WRW\U89X?1P"]A6:R,QOX+%,_A@C M%O M&3#1;N.BO.-:;>F_+I3OHMG?V%%[_@=02P,$% @ 8#]'6&CQ6EEHZ9T)+/#8;4M41F$0E#5[\[ M_$1^7S77(GW@0#60C&H#BOPZ9SQMQ?6XV:@WXEJ\*5- ;3R24@,M$D=G$=8[ M(8VX%9^W3D_)XQVYSJ,(,F09;$KE;*G89&K(#\F/)%==22& D;V4:;6I0SY#6UE$Y$T\M^S:RYLG[=P1?F$>A\])V8+.Q M3L9BI'A-J@G:K3T@F4)& M0V2 S)*MIM!-:OY1;YH[C58'77W-6CJ/="N3//4'=(OLK6%_A:Y::(O"1APV M&[6%3H-+V^0JJTIRZ,.8V,]/_5ZA32:F;,2>,$ ^J/(!4(_K9Y&A"REDMHRL M*KJ2R3P#8=QG1Z37PC"S[(FQ5%G>EX#D:6U-%8S; 7LRH0MF#7W?QSB?CXEC MEC,\,33+9AP"$FUT:*9P\ B3U[[%@H( %@9$"JD+8_W_9UV^7(%=CUZ9%%+@ MSM^ M#DI$T;*YF5)F?=FBPU*E4*JAW$<0U/^8#,%),*86-)0.8:O+TJ2&O^8WQK$9C%WN@*._AD%_\!LM#,>T15Q?7'L,.6],; M;&X^&6(:#Z55U%074M&G8W/J'9M'0*\XW:=7>&5T+*0M,P_T\&X$ZCN:FKNKH-KTZ3N>><1K212_%-+ Q6ZU, MWP)M;Y"J$]QK?(VS6?<,9R=-,(XR_%F'L M(\+X7X2^KCBUPU"/2CXSN_/[ M%H([,3S!N./;L3SQD^6CU(;RO]CL^-5%>01/.&ZY=A3]V9>Q\TE' 3V&6U%3 M75)%GXZ-/YLO]E86?YQ*<>0Z;U=774:[7ATG?S9<_D!_!D179ME\35);;'L,/FSS;*0'*6,,/$Y [_C!6SU@YC5J:L+K RMXZ6/YLICPKLD .\ M6LKO@]@[T>IA/#Y\6GPM0G7IO>9Z3?'$GSV4K=[TM)Z#^GJ6)7&\(5KBW7'U M9V-E ,G<6FS$HR$S_.!+R5U==;GM>G6<_-D]&2IJGY4;++.1//CO;DM474); M1AT>?_9'W!"[7B13*B9PS.W6YSD!-<.Q]5/+%3'%^GU%Q MY"-#>T)4E^"KMAU(?[9"UMU9X"PB-+/F5H]O'$FQ1%]YA"6>';__8;OD(MK) MRRT6V&>75T?LFWT2%TO^!E!+ 0(4 Q0 ( & _1UB:T$%G81( )!J . M " 0 !D-C'-D4$L! A0#% @ 8#]'6$T 58RJ!@ MI$D !0 ( !+2@ &EK="TR,#(T,#(P-U]L86(N>&UL4$L! M A0#% @ 8#]'6&CQ 0001750149 2024-02-07 2024-02-07 false 0001750149 8-K 2024-02-07 INHIBIKASE THERAPEUTICS, INC. DE 001-39676 26-3407249 3350 Riverwood Parkway SE Suite 1900 Atlanta GA 30339 (678) 392-3419 false false false false Common Stock, $0.001 par value IKT NASDAQ true false